Organic Active Ingredients TRIZ Cases

Chromane-substituted tetracyclic compounds inhibit HCV NS5A to stop viral replication and prevent liver disease progression.

Butyrate-containing triglycerides mask bitterness and odor to enable effective delivery, resolving rapid gastric lipolysis issues.

Serum biomarkers enable non-invasive detection of colorectal cancer lesions through mass spectrometry analysis.

Template removal creates secondary internal structures in carrier particles, resolving the contradiction between mechanical stability and disintegration time.

Galactoglucomannan-based pharmaceuticals treat lower urinary tract disorders by reducing adverse reactions while maintaining therapeutic efficacy.

Crystalline forms of triazolopyrimidine compound enhance aqueous solubility through controlled solvent crystallization.

Pyrido[2,3-d]pyrimidine derivatives form irreversible covalent bonds with FGFR cysteine residues to overcome limited therapeutic options.

Multi-particulate pharmaceutical compositions use cationic pH-dependent polymers to deter physical manipulation and non-medical injection.

Synergistic icaritin and quercetin composition reduces ALT and AST levels without cytotoxicity.

Urea derivatives inhibit uveal melanoma cell viability and migration, addressing metastasis risks during tumor removal.

Segmented chemical structures target integrase to delay AIDS onset while reducing toxicity and resistance.

Stiffening mature gametocytes overcomes deformability barriers, enabling spleen filtration to block Plasmodium falciparum transmission.

High-dimensional immune profiling identifies metabolic reprogramming in CD8 T cells as a predictive biomarker for disease severity.

Topical anhydrous rapamycin gel targets mTOR pathways to inhibit basal cell carcinoma proliferation in Gorlin syndrome patients.

Dissolving pimavanserin in compatible liquid vehicles enables enteral feeding tube delivery for patients with swallowing difficulties.

FN3-siRNA conjugates enable targeted cellular uptake, resolving plasma nuclease susceptibility and intracellular delivery bottlenecks.

Oral D-allulose activates hypothalamic neurons to promote oxytocin secretion, bypassing nasal delivery instability.

Safe harbor locus integration enables permanent AGXT gene corrections, resolving precision issues in Primary Hyperoxaluria Type 1 treatments.

Synthesizes diarylpyridine derivatives using organometallic reagents under mild conditions.

A pharmaceutical composition combining lactoferrin with multiple antiviral agents inhibits viral entry and replication.

Hydrolyzed collagen under 1,000 Daltons reduces healing time and scar formation by enabling rapid absorption into damaged tissues.

A polyvinyl alcohol matrix blends distinct molecular weights to create flexible oral thin films with high active ingredient content.

A composite topical composition delivers Ganoderma immunomodulatory proteins within a gel matrix to resolve slow healing rates in chronic wounds and ulcers.

Single-stranded binding moieties block direct association between particles, eliminating aggregation that degrades sequencing quality.

Preliminary IL-1β inhibition blocks inflammatory pathways to prevent acute gout flares during urate-lowering therapy, avoiding corticosteroid adverse effects.

N-methanocarbathymidine employs a locked northern conformation to inhibit viral replication, reducing postherpetic neuralgia severity.

Administering pridopidine increases default mode network connectivity, addressing insufficient cognitive improvement in Alzheimer's disease.

Alternating electric fields disrupt cationic-anionic polymer nanoparticles to trigger localized drug release at target sites.

Adamantane scaffolds mediate receptor occupancy and brain penetration while preventing desensitization through dynamic modulation.

Direct thioamide formation from 4-cyanopiperidine hydrochloride and hydrogen sulphide eliminates stoichiometric base consumption and aqueous waste generation.

N4-acetylcytidine and 5-hydroxymethyluridine modifications reduce innate immune response activation, enabling higher doses of RNA therapeutics.

RANKL polypeptide accelerates thymic epithelial cell regeneration and T-cell reconstitution after cytoablative bone marrow transplantation.

Segmented thieno-indole alkylating agents use DNA-binding moieties to target tumor cells, reducing systemic side effects on normal proliferating tissues.

Modular pyrido[3′,4′:4,5]pyrrolo[3,2-b][1,6]naphthyridine compounds overcome drug resistance by targeting CK2 enzyme activity.

Annexin A5 binds phosphatidylserine to mitigate distant organ damage from ischemia-reperfusion injury.

Optimized biguanide dosing schedules extend symptom relief duration, addressing limited effectiveness in current therapeutic interventions.

Naltrexone implantable tablets use biodegradable polymers to deliver controlled drug release for three months or more.

DNA methylation status in GABA and dopamine pathways detects CPSP susceptibility, resolving inconsistent genetic prediction.

Replaces beta blockers with immunosuppressive and anti-inflammatory agents to correct immune disorders, reducing side effects while reversing weight loss.

Phosphorylated neurofilament heavy chain levels serve as biomarkers to evaluate spinal muscular atrophy therapy effectiveness.

A pyrazolopyrimidine derivative inhibits ALK, TRK, and ROS1 kinases through specific heterocyclic structural modifications.

New naphthyridine compounds inhibit c-Met and VEGFR-2 kinases with superior anti-tumor efficacy.

Optimized azetidine compounds target pancreatic receptors to manage obesity and diabetes while reducing adverse effects.

Vitamin K supplementation reduces dp-ucMGP levels and thrombogenicity, addressing high mortality risks in severe COVID-19 cases.

In silico screening selects immunogenic HERV-derived epitopes to overcome limited cross-subtype applicability in cancer vaccine development.

Deuterated atazanavir isotopologues strengthen carbon-deuterium bonds to resist hepatic metabolism and improve pharmacokinetic profiles.

Targeted chemical agents restore mitochondrial energy production to improve fertilization rates in male infertility cases.

Ethyl eicosapentaenoate reduces triglycerides by up to 75% while maintaining or decreasing LDL-C levels in subjects receiving concomitant statin therapy.

Triazole-modified galactosides resist acidic hydrolysis while maintaining high affinity for galectin-1 and galectin-3 targets.

CRISPR-Cas9 deletes GLI1 intronic binding sites to reduce expression.

Allosteric inhibitor compounds overcome C797S mutation resistance in non-small cell lung cancer treatment.

Specific substituent patterns on the bicyclic core reduce off-target activity, addressing safety concerns while increasing HDL-C and lowering LDL-C.

Columnar chitosan acrylic powder absorbs liquid through radial swelling while maintaining structural integrity.

Cooling crystallization yields (S)-oxiracetam crystal form III, resolving the trade-off between production simplicity and insufficient solubility.

A supersaturated solution of active pharmaceutical ingredient in acetic acid and spray drying solvent enables higher API concentrations.

Optimized pyridyl substituents enhance IRAK-4 binding affinity, resolving specificity and efficacy trade-offs in inflammatory disease treatment.

Modified TLR9 agonist oligonucleotides convert cold tumors into hot tumors by enhancing cytokine production and anti-tumor immunity.

Fused bicyclic sulfamoyl derivatives inhibit hepatitis B virus replication through targeted structural modifications.

Hydrophilic treatment of apertured holes channels fluids into the core, reducing surface stains and rewet caused by viscoelastic body fluids.

Inhibiting SARM1 and NAMPT prevents Wallerian degeneration, preserving axons and enabling functional recovery.

Compounds of Formula I disrupt oncological signaling by targeting the conserved P-loop region across KRAS-G12C, G12D, and G12V mutants.

Combining SP-2577 with ABL2 pathway inhibitors overcomes resistance mechanisms in Ewing's Sarcoma treatment.

Segmented bupivacaine microparticles in a biodegradable hemostatic matrix extend anesthetic duration while preventing systemic absorption.

Oligonucleotide inhibitors suppress SARAF protein to destabilize persistent cccDNA templates and eliminate chronic hepatitis B reservoirs.

Compounds inhibit glutaminase C phosphorylation, reducing glutamate production and limiting tumor cell growth.

Maternal genetic compatibility resolves the contradiction between restoring cellular respiration and maintaining genetic integrity in modified eukaryotic cells.

A dual visco sealed-up technique injects layered viscoelastic substances to maintain anterior chamber depth during ophthalmic surgery.

A double-layer osmotic pump tablet uses a semi-permeable film and push layer to drive zero-order drug release.

Continuous flow microreactors control reaction ratios and times to produce flavan oligomers at desired polymerization degrees, reducing purification costs.

A polydextrose and galacto-oligosaccharide blend optimizes short-chain fatty acid profiles in infant formulas.

TPGS and non-ionizable cellulosic polymer prevent nanoparticle aggregation and crystallization, enhancing bioavailability.

Nucleic acid agents targeting snRNA U6atac inhibit minor spliceosome activity, overcoming resistance in advanced prostate cancer.

JNK3 inhibitor compounds target specific kinase activity to reduce beta-amyloid plaques and increase neuron numbers.

Sulfoximine substituted quinazoline derivatives inhibit MNK1 and MNK2 kinases, addressing underlying inflammation in metabolic disorders.

Novel cinnamamide derivatives inhibit STAT3 activity to suppress cancer cell growth.

Centrifugal spinning creates 3D nanofiber wound dressings that resolve solvent defects and improve mechanical homogeneity for sustained drug delivery.

Transient Tip60 inhibitor administration triggers cardiomyocyte proliferation to regenerate heart tissue.

Internucleotide linkage modifications enable selective reabsorption by kidney proximal tubule cells, resolving non-specific entrapment during filtration.

DDR pathway biomarkers identify cancer patients sensitive to MDM2 antagonist treatment, avoiding complex multi-gene testing.

Replacing naltrexone's hydroxyl group with fluorine minimizes gastrointestinal side effects while maintaining efficacy in preventing cannabis relapse.

Optimized sodium starch glycolate concentration resolves the contradiction between tablet hardness and drug release efficiency.

Segmented bicyclic oxa-lactam compounds target Syk kinase to treat inflammatory diseases without off-target effects.

Polycyclic compounds inhibit resistant ALK mutations via parameter changes, extending therapeutic duration.

Covalent binding to KRAS G12C cysteine residues locks mutant proteins in inactive GDP-bound states, disrupting downstream signaling pathways.

Chitosan mediates antibody-virus interactions to resolve trade-offs between detection sensitivity and administration ease.

Combines onion bulb extract with low-dose glucocorticosteroids to modulate EGFR signaling pathways for potent anti-inflammatory effects.

Secreted PCAST proteins serve as molecular markers for pancreatic cancer detection in biological samples.

Controlled crosslinking and neutralization improve hyaluronic acid filler stability while limiting excessive swelling.

Fluorinated pyrazole capsid inhibitors enhance bioavailability and reduce dosing frequency to address drug resistance and toxicity.

Plant extracts containing gallic acid and gallotannins inhibit Eimeria sporozoites, avoiding drug resistance while reducing lesion scores.

A macrocyclic tyrosine kinase inhibitor compound with specific structural features inhibits TRK, ALK, and ROS1 kinases.